23547837Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JCLeukemia & lymphomaAntibodies, Monoclonal, Humanized; Antineoplastic Agents; Leukemia, Lymphocytic, Chronic, B-CellAdult; Aged; Aged, 80 and over; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Mutation; Neoplasm Staging; Remission InductionPatients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma. 2013 Dec; 54(12):2654-9.Leuk Lymphoma2013-05-09T00:00:002013Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000369Living Beings93664810.461329Aged, 80 and overD000368Living Beings1341183530.29479AgedD000328Living Beings1578255770.254454AdultD000970Chemicals & Drugs40723510.435494Antineoplastic AgentsD000971Procedures30624340.47627Antineoplastic Combined Chemotherapy ProtocolsD007143Chemicals & Drugs431310.959345Immunoglobulin Heavy ChainsD008875Concepts & IdeasLiving Beings1473249570.258834Middle AgedD009154Physiology70239520.442682MutationD009367Concepts & IdeasProcedures34719320.6701Neoplasm StagingD005260Physiology1992444050.191184FemaleD006801Living Beings2262862810.130064HumansD015451Disorders571360.907621Leukemia, Lymphocytic, Chronic, B-CellD008297Physiology1931408600.201635MaleMedicine-Hematology and OncologyD061067Chemicals & Drugs2139290.656201Antibodies, Monoclonal, HumanizedD060830Procedures12220.984801Consolidation ChemotherapyD00007432324830.973881AlemtuzumabD012074Procedures1657220.853042Remission InductionUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professortrue1ProfessorProfessorAuthorship 6715170.1175350.1175351authors10.2517has subject area